PROVE-IT study
Jump to navigation
Jump to search
Introduction
4162 patients hospitalized with acute coronary syndrome
Patients randomized to:
- pravastatin 40 mg or atorvastatin 80 mg daily
At 24 months, median LDL cholesterol levels
- 95 mg/dL in pravastatin group
- 62 mg/dL in atorvastatin group
Combined endpoint of:
Results:
- combined endpoint reached less frequently in atorvastin group 22% vs 26%
- lower LDL cholesterol & lower CRP levels independently associated with better outcomes
More general terms
Additional terms
References
- ↑ Journal Watch 24(9):69-70, 2004 Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. Epub 2004 Mar 08. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15007110
- ↑ Journal Watch 25(3):21, 2005 Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15635109